Regenerative Medicine

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.

Avant Technologies is evaluating a therapy to protect insulin cells from immune attack, a breakthrough that could end the need for harsh drugs.

Carrying the Alzheimer's gene, a longevity expert has turned himself into a public experiment, documenting his radical protocol to prevent the disease.

A new partnership aims to bring a revolutionary, disease-modifying stem cell therapy for knee osteoarthritis to millions of patients in Greater China.

Juvena Therapeutics lands a $33.5M Series B and a major pharma deal to advance its AI-discovered regenerative drugs for neuromuscular diseases.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

A Houston biotech reports a 100% response rate with its new CAR-T therapy, offering a potential lifeline for patients with a devastatingly rare cancer.